Kai Beckmann, a member of the executive board and the CEO Electronics at Merck KgaA, discusses the use of AI in the ...
Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...
Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...
Shares of Merck KGaA surged after the company confirmed its outlook for fiscal year 2024 and revisions to its mid-term sales ...
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...